What data sources does EL7.AI use?

EL7.AI uses official data from the Federal Reserve (FOMC), European Central Bank, CFTC (COT reports), BLS, FRED, FMP for prices, and 15+ news sources.

What is the DLS system?

Dictionary-based Linguistic Scoring — a proprietary tone analysis system using a dictionary of 800+ categorized phrases. Reproducible and verifiable results, unlike random AI analysis.

How is EL7.AI different from Bloomberg?

Bloomberg takes years to master and costs $25,000/year. EL7.AI offers the same institutional data with built-in AI analysis at $500/year, with full Arabic support.

What markets are covered?

Stocks from 7 exchanges (NYSE, NASDAQ, LSE, TSE, HKSE, Euronext, XETRA, Tadawul), 28 forex pairs, 300+ cryptocurrencies, 50+ indices, and 40+ commodities.

Is EL7.AI available in Arabic?

Yes! EL7.AI is an Arabic-first platform — everything is available in Arabic with full RTL support: interface, analysis, news, and reports.

How much does EL7.AI cost?

Founding member pricing starts at $500/year (Batch 1). The price is locked forever at this level. Regular pricing will be $1,000/year after official launch.

Is there a refund policy?

Yes — full refund within 7 days of purchase. If you're not satisfied, contact us for a complete refund.

Bank of Japan and Bank of England with DLS, advanced crypto module, enhanced trading signals, and mobile app. All future features are included in your subscription.

BeOne Medicines (ONC) Maintains 'Strong Buy' Rating Amid Robust Brukinsa Sales and FDA Catalysts

BeOne Medicines (ONC) continues to demonstrate strong market momentum, supported by a 'Strong Buy' rating and a 12-month price target of $410 per share. The company's flagship drug, Brukinsa, reported a stellar 49% year-over-year growth in sales, reaching $3.93 billion in 2025. This performance solidifies the firm's leadership in the Chronic Lymphocytic Leukemia (CLL) market as it approaches a critical profitability inflection point. Looking ahead to 2026, investors are focused on several high-impact catalysts, including potential FDA approvals for Sonrotoclax and BTK-CDAC. Despite a modest miss in its 2026 guidance, the robust pipeline and core product growth suggest a positive long-term outlook for the biotech firm.

BeOne Medicines (ONC) Maintains 'Strong Buy' Rating Amid Robust Brukinsa Sales and FDA Catalysts

Key Facts

Instruments